ALVO vs. RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, BBIO, BPMC, and ELAN
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.
Alvotech vs.
Dr. Reddy's Laboratories (NYSE:RDY) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.
Dr. Reddy's Laboratories received 315 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 59.41% of users gave Dr. Reddy's Laboratories an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
Dr. Reddy's Laboratories presently has a consensus price target of $17.00, suggesting a potential upside of 18.59%. Alvotech has a consensus price target of $18.00, suggesting a potential upside of 77.17%. Given Alvotech's stronger consensus rating and higher possible upside, analysts plainly believe Alvotech is more favorable than Dr. Reddy's Laboratories.
Dr. Reddy's Laboratories has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.
3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Dr. Reddy's Laboratories has higher revenue and earnings than Alvotech. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Dr. Reddy's Laboratories has a net margin of 17.25% compared to Alvotech's net margin of -123.47%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Alvotech's return on equity.
In the previous week, Alvotech had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Alvotech and 13 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.63 beat Alvotech's score of 0.53 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.
Summary
Dr. Reddy's Laboratories beats Alvotech on 13 of the 18 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
This page (NASDAQ:ALVO) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ALVO Stock Free ALVO Stock Alerts